Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02446340
Recruitment Status : Completed
First Posted : May 18, 2015
Last Update Posted : May 18, 2015
Sponsor:
Information provided by (Responsible Party):
Kineta Inc.

Brief Summary:
The purpose of this study is to examine safety outcomes in healthy volunteers after systemic administration of multiple ascending doses of dalazatide.

Condition or disease Intervention/treatment Phase
Healthy Drug: dalazatide Drug: placebo Phase 1

Detailed Description:
The purpose of this study is to examine safety outcomes in healthy volunteers after systemic administration of multiple ascending doses of dalazatide delivered via subcutaneous injection twice per week for a total of 9 doses.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: A Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ShK-186
Study Start Date : November 2013
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014

Arm Intervention/treatment
Experimental: dalazatide 5ug
8 subjects, 6 given active agent and 2 given placebo
Drug: dalazatide
Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
Other Name: ShK-186

Drug: placebo
Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
Other Name: Sub Q Placebo

Experimental: dalazatide 15ug
8 subjects, 6 given active agent and 2 given placebo
Drug: dalazatide
Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
Other Name: ShK-186

Drug: placebo
Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
Other Name: Sub Q Placebo

Experimental: dalazatide 30ug
8 subjects, 6 given active agent and 2 given placebo
Drug: dalazatide
Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
Other Name: ShK-186

Drug: placebo
Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
Other Name: Sub Q Placebo

Experimental: dalazatide 60ug
8 subjects, 6 given active agent and 2 given placebo
Drug: dalazatide
Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
Other Name: ShK-186

Drug: placebo
Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
Other Name: Sub Q Placebo




Primary Outcome Measures :
  1. Subjects with adverse events [ Time Frame: From randomization to Day 57 (14 time points) ]

Secondary Outcome Measures :
  1. Subjects with changes in vital signs [ Time Frame: From randomization through Day 57 (14 time points) ]
    Vital signs include temperature, respiratory rate, supine blood pressure and pulse.

  2. Subjects with changes in symptom-directed physical examinations [ Time Frame: From date of randomization to day 57 (14 timepoints) ]
  3. Subjects with changes in 12-lead electrocardiograms [ Time Frame: From date of randomization to day 57 (5 timepoints) ]
  4. PK parameters [ Time Frame: pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 4 hours post dose, 8 hours post dose, 12 hours post dose ]
    Parameters include Area under the plasma concentration versus time curve of dalazatide (AUC)

  5. Presence of specific anti-drug antibody [ Time Frame: From date of randomization through Day 57 (4 timepoints). ]
    Serum evaluated for specific anti-drug antibody using ELISA-based immunoassay.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. healthy normal male and female subjects, ages 18 to 45, inclusive;
  2. able to communicate and able to provide valid, written informed consent;
  3. within the body mass index (BMI) range of approximately 18.0 to 30.0 kg/m2, inclusive;
  4. minimum weight of 50 kg;
  5. willingness to remain totally abstinent or use adequate contraception; e.g., 2 of the following methods: hormonal contraceptive, intrauterine device, condom, diaphragm, and spermicidal gel/foam) in order to prevent pregnancy from the screening visit until 60 days after the follow-up visit. For men, the donation of sperm during this period is also prohibited.

Exclusion Criteria:

  1. the presence of clinically significant medical history as determined by the investigator.
  2. the history of clinically significant cardiac abnormalities or presence of clinically significant abnormality on 12-lead ECG.
  3. the history of pre-existing paresthesia or neuropathy;
  4. abnormalities on neurologic exam at screening or baseline
  5. the history of any cancer requiring systemic chemotherapy or radiation; individuals with a history of non-melanoma skin cancer, nonrecurring carcinoma in situ treated with laser or cryotherapy or cervical cancer-in-situ, resected surgically with no evidence of disease, may be accepted on a case by case basis at the discretion of the Investigator;
  6. the presence of acute infection or history of acute infection within 7 days prior to receipt of the study drug; additionally, oral temperature may not exceed 37.4°C at baseline;
  7. the presence of clinically significant laboratory abnormalities (chemistry panel of 20 analytes [Chem-20; fasted 10-12 hours], complete blood count [CBC], and urinalysis [UA]) as determined by the investigator;
  8. positive urine drug screen for drugs of abuse (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines, cotinine, tricyclic antidepressants and alcohol) at Screening or at Baseline.
  9. typical intake of more than 7 units of alcohol per week (one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
  10. a positive hepatitis screen (Hepatitis BsAg or anti-HCV) or positive Human Immunodeficiency Virus (HIV) antibody test ;
  11. a history of multiple drug allergies that are important in the view of the Investigator;
  12. any history of anaphylaxis or a history of allergy to a medication, diet, or environmental exposure (including bee stings) that are important in the view of the Investigator;
  13. participation in another clinical trial with receipt of an investigational product within 60 days of dose administration (or 5 half lives, whichever is longer);
  14. recent (within 1 year of Screening) history of illicit drug use;
  15. history of alcohol abuse that is important in the view of the Investigator
  16. inadequate venous access that would interfere with obtaining blood samples;
  17. use of prescription medications, over the counter products, herbal remedies and nutritional supplements within 7 days of study drug administration and throughout the study, or the anticipated need for prescription medications prior to Study Completion;
  18. recipients of blood transfusion or transfusion of blood or plasma products within 60 days of study drug administration;
  19. donation of blood > 500 mL within 2 months of study drug administration;
  20. positive pregnancy test at screening or at baseline (female subjects only);
  21. history within the past 3 months of eating disorders or other conditions which may lead to suspicion about the participant's nutritional status;
  22. inability or unwillingness to comply with study restrictions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02446340


Locations
Layout table for location information
United States, Kansas
PRA International
Lenexa, Kansas, United States, 66219
Sponsors and Collaborators
Kineta Inc.
Investigators
Layout table for investigator information
Study Chair: Shawn Iadonato, PhD Kineta Inc.
Layout table for additonal information
Responsible Party: Kineta Inc.
ClinicalTrials.gov Identifier: NCT02446340    
Other Study ID Numbers: 186-02
First Posted: May 18, 2015    Key Record Dates
Last Update Posted: May 18, 2015
Last Verified: May 2015
Keywords provided by Kineta Inc.:
ShK-186
dalazatide
Kv1.3
SHK